Price Action Don’t Lie: Is Apricus Biosciences Inc’s Fuel Running Low? The Stock Reaches 52 Week Low Today

Price Action Don't Lie: Is Apricus Biosciences Inc's Fuel Running Low? The Stock Reaches 52 Week Low Today

The stock of Apricus Biosciences Inc (NASDAQ:APRI) hit a new 52-week low and has $1.87 target or 12.00% below today’s $2.12 share price. The 8 months bearish chart indicates high risk for the $15.60M company. The 1-year low was reported on Oct, 31 by Barchart.com. If the $1.87 price target is reached, the company will be worth $1.87 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 19,953 shares traded hands. Apricus Biosciences Inc (NASDAQ:APRI) has declined 63.71% since March 29, 2016 and is downtrending. It has underperformed by 67.18% the S&P500.

Analysts await Apricus Biosciences Inc (NASDAQ:APRI) to report earnings on November, 3. They expect $-0.07 earnings per share, up 30.00% or $0.03 from last year’s $-0.1 per share. After $-0.08 actual earnings per share reported by Apricus Biosciences Inc for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

Apricus Biosciences Inc (NASDAQ:APRI) Ratings Coverage

Out of 5 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Apricus Bioscience Inc has been the topic of 6 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Sterne Agee CRT on Wednesday, December 9. On Friday, November 6 the stock rating was maintained by FBR Capital with “Outperform”. Ascendiant Capital Markets initiated the shares of APRI in a report on Thursday, August 13 with “Buy” rating. The company was downgraded on Friday, November 6 by Roth Capital. The stock of Apricus Biosciences Inc (NASDAQ:APRI) has “Neutral” rating given on Friday, November 6 by TH Capital.

According to Zacks Investment Research, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ®. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.”

More news for Apricus Biosciences Inc (NASDAQ:APRI) were recently published by: Seekingalpha.com, which released: “Reverse Stock Split: Apricus Bio” on October 31, 2016. Globenewswire.com‘s article titled: “Apricus Biosciences Announces Approval of Vitaros® for the Treatment of …” and published on October 26, 2016 is yet another important article.

APRI Company Profile

Apricus Biosciences, Inc., incorporated on October 20, 1987, is a pharmaceutical company, which develops pharmaceutical products. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. It has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Firm has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment